MCID: CNG069
MIFTS: 47

Congenital Cytomegalovirus

Categories: Fetal diseases, Rare diseases

Aliases & Classifications for Congenital Cytomegalovirus

MalaCards integrated aliases for Congenital Cytomegalovirus:

Name: Congenital Cytomegalovirus 54
Congenital Cytomegalovirus Infection 74

Classifications:



External Ids:

ICD10 34 P35.1
UMLS 74 C0158945

Summaries for Congenital Cytomegalovirus

NIH Rare Diseases : 54 Congenital cytomegalovirus (congenital CMV) is a group of symptoms that may occur when an infant is infected with the cytomegalovirus before birth. Most infants who are infected with the virus never develop symptoms of the condition. However, approximately 10% of babies will experience health problems and/or disabilities such as problems with the lungs, liver and/or spleen at birth; hearing loss; vision loss; intellectual disability; seizures; small head size; and/or lack of coordination. Some babies with the condition may have evidence of infection at birth, while others may not develop symptoms for two or more years. Congenital CMV occurs when a mother is infected with cytomegalovirus during pregnancy and passes the infection to the fetus through the placenta. Treatment is based on the signs and symptoms present in each person.

MalaCards based summary : Congenital Cytomegalovirus, also known as congenital cytomegalovirus infection, is related to cytomegalovirus infection and toxoplasmosis. An important gene associated with Congenital Cytomegalovirus is GJB2 (Gap Junction Protein Beta 2), and among its related pathways/superpathways are Influenza A and NF-kappaB Signaling. The drugs Antiviral Agents and Anti-Infective Agents have been mentioned in the context of this disorder. Affiliated tissues include placenta, lung and liver, and related phenotypes are immune system and integument

Related Diseases for Congenital Cytomegalovirus

Diseases related to Congenital Cytomegalovirus via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 212)
# Related Disease Score Top Affiliating Genes
1 cytomegalovirus infection 31.6 CCL2 IL1B TNF
2 toxoplasmosis 29.4 IL1B TLR2 TNF
3 pneumonia 29.0 CCL2 IL1B TLR2 TNF
4 meningitis 28.8 CCL2 IL1B TLR2 TNF
5 lung disease 28.8 CCL2 IL1B TLR2 TNF
6 ataxia, combined cerebellar and peripheral, with hearing loss and diabetes mellitus 10.5
7 deafness, autosomal dominant 24 10.4 GJB2 GJB6
8 purulent labyrinthitis 10.4 CCL2 IL1B
9 kid syndrome 10.4 GJB2 GJB6
10 retinitis pigmentosa 73 10.4 CCL2 IL1B
11 pseudoainhum 10.4 GJB2 GJB6
12 knuckle pads 10.4 GJB2 GJB6
13 knuckle pads, leukonychia, and sensorineural deafness 10.4 GJB2 GJB6
14 deafness, x-linked 2 10.4 GJB2 GJB6
15 sensorineural hearing loss 10.4
16 dfnb1 10.3 GJB2 GJB6
17 vohwinkel syndrome 10.3 GJB2 GJB6
18 deafness, autosomal recessive 1a 10.3 GJB2 GJB6
19 deafness, autosomal recessive 23 10.3 GJB2 GJB6
20 deafness, autosomal recessive 7 10.3 GJB2 MT-RNR1
21 deafness, autosomal dominant 36 10.3 GJB2 MT-RNR1
22 vestibular disease 10.2 GJB2 GJB6
23 idiopathic bilateral vestibulopathy 10.2 MT-RNR1 RNR1
24 erythrokeratodermia variabilis et progressiva 1 10.2 GJB2 GJB6
25 exudative glomerulonephritis 10.2 IL1B TNF
26 staphylococcal toxic shock syndrome 10.2 IL1B TNF
27 deafness, autosomal recessive 30 10.2 GJB2 MT-RNR1
28 kashin-beck disease 10.2 IL1B TNF
29 hodgkin's lymphoma, nodular sclerosis 10.2 GJB2 GJB6 MT-RNR1
30 vulvar vestibulitis syndrome 10.2 IL1B TNF
31 burns 10.2 IL1B TNF
32 fetal cytomegalovirus syndrome 10.2
33 deafness, autosomal dominant 2a 10.2 GJB2 GJB6
34 glossitis 10.2 IL1B TNF
35 laryngitis 10.2 IL1B TNF
36 auditory system disease 10.2 GJB2 GJB6 MT-RNR1
37 cerebral artery occlusion 10.2 IL1B TNF
38 opisthorchiasis 10.2 IL1B TNF
39 anthracosis 10.2 CCL2 TNF
40 retinitis pigmentosa 60 10.2 IL1B TNF
41 irritant dermatitis 10.2 IL1B TNF
42 acute vascular insufficiency of intestine 10.2 IL1B TNF
43 actinic prurigo 10.2 IL1B TNF
44 deafness, autosomal recessive 16 10.2 GJB2 GJB6
45 osteosclerotic myeloma 10.1 IL1B TNF
46 crohn's colitis 10.1 IL1B TNF
47 poems syndrome 10.1 IL1B TNF
48 autoimmune gastritis 10.1 IL1B TNF
49 central nervous system vasculitis 10.1 IL1B TNF
50 autoimmune myocarditis 10.1 PPARG TNF

Graphical network of the top 20 diseases related to Congenital Cytomegalovirus:



Diseases related to Congenital Cytomegalovirus

Symptoms & Phenotypes for Congenital Cytomegalovirus

MGI Mouse Phenotypes related to Congenital Cytomegalovirus:

47
# Description MGI Source Accession Score Top Affiliating Genes
1 immune system MP:0005387 9.56 CCL2 GJB2 GJB6 IL1B PPARG RNASET2
2 integument MP:0010771 9.1 GJB2 GJB6 IL1B PPARG TLR2 TNF

Drugs & Therapeutics for Congenital Cytomegalovirus

Drugs for Congenital Cytomegalovirus (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 22)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1 Antiviral Agents Phase 4,Phase 3,Phase 2,Phase 1
2 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1
3 valacyclovir Phase 4,Phase 2,Phase 3
4
Valganciclovir Approved, Investigational Phase 3,Phase 2,Phase 1 175865-60-8 64147
5
Ganciclovir Approved, Investigational Phase 3,Phase 1,Phase 2 82410-32-0 3454
6
Mannitol Approved, Investigational Phase 3 69-65-8 453 6251
7
Povidone Approved Phase 3 9003-39-8
8 Pharmaceutical Solutions Phase 3,Phase 2
9 gamma-Globulins Phase 3,Not Applicable
10 Immunoglobulins, Intravenous Phase 3,Not Applicable
11 Immunoglobulins Phase 3,Phase 1,Phase 2,Not Applicable
12 Rho(D) Immune Globulin Phase 3,Not Applicable
13 Antibodies Phase 3,Phase 1,Phase 2,Not Applicable
14 Nucleic Acid Synthesis Inhibitors Phase 3,Phase 1,Phase 2
15 Ganciclovir triphosphate Phase 3,Phase 1,Phase 2
16 Sodium Benzoate Phase 3
17 Immunoglobulin G Phase 3
18 Immunologic Factors Phase 1, Phase 2,Phase 2,Not Applicable
19 Antibodies, Monoclonal Phase 1, Phase 2
20 MF59 oil emulsion Phase 2
21 Vaccines Phase 2,Phase 1,Not Applicable
22 polysaccharide-K

Interventional clinical trials:

(show all 38)
# Name Status NCT ID Phase Drugs
1 In UTERO Treatment of Cytomegalovirus Congenital Infection With Valacyclovir Terminated NCT01037712 Phase 4 Valacyclovir (ZELITREX);Placebo
2 Congenital Cytomegalovirus: Efficacy of Antiviral Treatment Unknown status NCT02005822 Phase 3 Valganciclovir
3 A Phase III Study to Evaluate the Safety and Efficacy of Ganciclovir (Dihydroxypropoxymethyl Guanine [DHPG]) Treatment of Symptomatic Central Nervous System (CNS) Congenital Cytomegalovirus (CMV) Infections. Completed NCT00001100 Phase 3 ganciclovir
4 Phase III Randomized, Controlled Study of Ganciclovir for Symptomatic Congenital Cytomegalovirus Infection Completed NCT00004278 Phase 3 ganciclovir
5 Short-Term vs. Long-Term Valganciclovir Therapy for Symptomatic Congenital CMV Infections Completed NCT00466817 Phase 3 Valganciclovir
6 Evaluation of the Benefit of Antiviral Treatment With Valganciclovir on Congenital CMV Infection-related Deafness on Hearing and Balance Recruiting NCT02606266 Phase 2, Phase 3 Valganciclovir
7 Valacyclovir to Prevent Vertical Transmission of Cytomegalovirus After Maternal Primary Infection During Pregnancy Recruiting NCT02351102 Phase 2, Phase 3 Valacyclovir;Placebo
8 A Randomized Trial to Prevent Congenital Cytomegalovirus (CMV) Active, not recruiting NCT01376778 Phase 3 CMV hyperimmune globulin
9 Randomized Controlled Trial of Valganciclovir for Cytomegalovirus Infected Hearing Impaired Infants Enrolling by invitation NCT03107871 Phase 3 Valganciclovir;Simple Syrup
10 Myocardial Screening in Fetuses With Congenital Cytomegalovirus (CMV) Infection Not yet recruiting NCT02787382 Phase 3
11 Congenital Cytomegalovirus: Efficacy of Antiviral Treatment in a Randomized Controlled Trial Terminated NCT01655212 Phase 3 Valganciclovir
12 Valganciclovir in Congenital CMV Infants Completed NCT00031434 Phase 1, Phase 2 Valganciclovir;Ganciclovir
13 Phase I/II Study of Human Anti-Cytomegalovirus (CMV) Monoclonal Antibody MSL-109 in Newborns With Symptomatic Congenital CMV Infection Without Central Nervous System Disease Completed NCT00004642 Phase 1, Phase 2 SDZ MSL-109
14 Recombinant CMV gB Vaccine in Postpartum Women Completed NCT00125502 Phase 2 MF59 adjuvant;Placebo
15 Valganciclovir Therapy in Infants and Children With Congenital CMV Infection and Hearing Loss Recruiting NCT01649869 Phase 2 Valganciclovir
16 Asymptomatic Congenital CMV Treatment Not yet recruiting NCT03301415 Phase 2 Valganciclovir
17 Safety, Tolerability, and Immunogenicity of a Cytomegalovirus DNA Vaccine Withdrawn NCT02594566 Phase 1 CyMVectin
18 Evaluation of the Safety and Efficacy of Standard Intravenous Immunoglobulins in Pregnant Women With Primary Cytomegalovirus Infection Unknown status NCT01659684 Not Applicable
19 Genotyping of Cytomegalovirus From Patients in Israel Unknown status NCT00228202
20 Screening for Congenital Cytomegalovirus Infection in Newborns Completed NCT02683096
21 A Cross-sectional Study of Congenital Cytomegalovirus Infection in Newborns in China Completed NCT02710864
22 The Benefits Feasibility and Acceptability of Extended Screening Testing in Newborn Babies Who Are Referred for Further Hearing Assessment Completed NCT01162330
23 Clinical Trial of Behavioral Modification to Prevent Congenital Cytomegalovirus Completed NCT01819519 Not Applicable
24 Cytomegalovirus Testing and Intervention Protocol for Newborn Nursery and Newborn Intensive Care Unit Completed NCT02680743 Not Applicable
25 Neonatal CMV-Ganciclovir Follow-up Study Completed NCT00031421
26 Study of the Transmission of Cytomegalovirus (CMV) Infection From Mother to Foetus Completed NCT01251744 Not Applicable
27 Does Normal Brain Imaging Predict Normal Neurodevelopmental Outcome in Fetuses With Proven Cytomegalovirus Infection? Completed NCT00872703
28 Assesment of Olfactory Disorders and Performance of a New Olfactory Test in Children With Congenital CMV Recruiting NCT02782988
29 Epidemiology of Congenital Cytomegalovirus in a High HIV Prevalence Setting, South Africa Recruiting NCT03722615
30 Reducing Acquisition of CMV Through Antenatal Education Recruiting NCT03511274 Not Applicable
31 Biomarkers of Cytomegalovirus Fetal Infection and Disease Recruiting NCT03090841
32 Immunological Characteristics of Maternal-fetal Transmission of Cytomegalovirus in Pregnancy Recruiting NCT02129465
33 Relevance of Gastric Aspirate in HCMV Detection Recruiting NCT03262194
34 Diagnosis of Congenital CMV Infection in Neonates Who Failed Newborn Hearing Screening Active, not recruiting NCT02139423 Not Applicable
35 Prognostic Value of Neonatal Markers for the Development of Neurosensorial Sequelae in Children Infected by Cytomegalovirus in Utero Active, not recruiting NCT01923636 Not Applicable
36 A Cohort Study of Cytomegalovirus(CMV) Infection Among Pregnant Women and Their Newborns in China Active, not recruiting NCT02645396
37 Development of Potential Biomarkers for Foetal Brain Development After Congenital CMV Infection Not yet recruiting NCT03188679 Not Applicable
38 Cytomegalovirus (CMV) Vaccines: Reinfection and Antigenic Variation Withdrawn NCT03443791 Not Applicable

Search NIH Clinical Center for Congenital Cytomegalovirus

Genetic Tests for Congenital Cytomegalovirus

Anatomical Context for Congenital Cytomegalovirus

MalaCards organs/tissues related to Congenital Cytomegalovirus:

42
Placenta, Lung, Liver, Spleen, Brain, Testes, Fetal Brain

Publications for Congenital Cytomegalovirus

Articles related to Congenital Cytomegalovirus:

(show top 50) (show all 885)
# Title Authors Year
1
Magnetic resonance imaging of cerebellar cysts in a neonate with congenital cytomegalovirus infection. ( 30612159 )
2019
2
Prevalence of Congenital Cytomegalovirus Infection and Associated Risk of In-utero HIV Acquisition in a High HIV Prevalence Setting, South Africa. ( 30615106 )
2019
3
Saliva Swab for Diagnosing Congenital Cytomegalovirus. ( 30667490 )
2019
4
Prediction of the Outcome of Cochlear Implantation in the Patients with Congenital Cytomegalovirus Infection based on Magnetic Resonance Imaging Characteristics. ( 30682778 )
2019
5
Histopathological analysis of placentas with congenital cytomegalovirus infection. ( 30712668 )
2019
6
Association between neuroimaging findings and neurological sequelae in patients with congenital cytomegalovirus infection. ( 30857789 )
2019
7
Direct Saliva Real-time Polymerase Chain Reaction Assay Shows Low Birth Prevalence of Congenital Cytomegalovirus Infection in Urban Western India. ( 30882739 )
2019
8
Efficacy of Valganciclovir Treatment Depends on the Severity of Hearing Dysfunction in Symptomatic Infants with Congenital Cytomegalovirus Infection. ( 30893926 )
2019
9
Integration of congenital cytomegalovirus screening within a newborn hearing screening programme. ( 30916438 )
2019
10
Congenital cytomegalovirus, parvovirus and enterovirus infection in Mozambican newborns at birth: A cross-sectional survey. ( 29538464 )
2018
11
Racial and Ethnic Differences in the Prevalence of Congenital Cytomegalovirus Infection. ( 29784513 )
2018
12
Risk Factors, Geographic Distribution, and Healthcare Burden of Symptomatic Congenital Cytomegalovirus Infection in the United States: Analysis of a Nationally Representative Database, 2000-2012. ( 29706491 )
2018
13
Hearing Trajectory in Children with Congenital Cytomegalovirus Infection. ( 29557247 )
2018
14
Unusual complication of fulminant congenital cytomegalovirus infection. ( 29843259 )
2018
15
Cost-effectiveness of universal and targeted newborn screening for congenital cytomegalovirus infection. ( 29359492 )
2018
16
Hematologic Adverse Events Associated with Prolonged Valganciclovir Treatment in Congenital Cytomegalovirus Infection. ( 29677086 )
2018
17
Neonates with congenital Cytomegalovirus and hearing loss identified via the universal newborn hearing screening program. ( 29571077 )
2018
18
Advancing our understanding of protective maternal immunity as a guide for development of vaccines to reduce congenital cytomegalovirus infections. ( 29343580 )
2018
19
Viral Loads in Congenital Cytomegalovirus Infection From a Highly Immune Population. ( 29860410 )
2018
20
Does screening for congenital cytomegalovirus at birth improve longer term hearing outcomes? ( 29705727 )
2018
21
Cochlear implant performance in children deafened by congenital cytomegalovirus-A systematic review. ( 29768731 )
2018
22
A rational approach to identifying newborns with hearing loss caused by congenital cytomegalovirus infection by dried blood spot screening. ( 29513124 )
2018
23
Congenital Cytomegalovirus Infection Presenting with Isolated Secretory Diarrhoea Mimicking a Congenital Diarrhoeal Disorder. ( 29611315 )
2018
24
Congenital cytomegalovirus pneumonitis and treatment response evaluation using viral load during ganciclovir therapy: a case report. ( 29709989 )
2018
25
Results of a Targeted Screening Program for Congenital Cytomegalovirus Infection in Infants Who Fail Newborn Hearing Screening. ( 29373759 )
2018
26
Sensorineural Hearing Loss and Congenital Cytomegalovirus Infection. ( 29441223 )
2018
27
Congenital Cytomegalovirus Infection and the Occurrence of Cystic Periventricular Leukomalacia. ( 29217314 )
2018
28
Closer to Universal Newborn Screening for Congenital Cytomegalovirus Infection but Far Away from Antiviral Therapy in All Infected Infants. ( 29703574 )
2018
29
Congenital Cytomegalovirus Infection: Update on Treatment: Scientific Impact Paper No. 56. ( 29139205 )
2018
30
The Burden of Congenital Cytomegalovirus Infection: A Prospective Cohort Study of 20 000 Infants in Finland. ( 29554325 )
2018
31
Valganciclovir Is Beneficial in Children with Congenital Cytomegalovirus and Isolated Hearing Loss. ( 29605391 )
2018
32
Contribution of Breastfeeding to False Positive Saliva PCR for Newborn Congenital Cytomegalovirus Screening. ( 29401303 )
2018
33
Brain Magnetic Resonance Imaging Findings of Congenital Cytomegalovirus Infection as a Prognostic Factor for Neurological Outcome. ( 29681488 )
2018
34
Clinical characteristics, audiological and neurodevelopmental outcomes of newborns with congenital cytomegalovirus infection. ( 29894555 )
2018
35
The Natural History and Rehabilitative Outcomes of Hearing Loss in Congenital Cytomegalovirus: A Systematic Review. ( 29912824 )
2018
36
Clinical factor associated with congenital cytomegalovirus infection in pregnant women with non-primary infection. ( 29735300 )
2018
37
Healthcare costs attributable to congenital cytomegalovirus infection. ( 29363491 )
2018
38
Reply to the Letter: "Sensorineural Hearing Loss and Congenital Cytomegalovirus Infection". ( 29443330 )
2018
39
Bronchopulmonary Dysplasia in Very Preterm Infants with Symptomatic Congenital Cytomegalovirus Infection: A Propensity Score- Matched Analysis. ( 30270170 )
2018
40
Congenital cytomegalovirus in Japan: More than 2 year follow up of infected newborns. ( 29032597 )
2018
41
Maternal and child human leukocyte antigens in congenital cytomegalovirus infection. ( 29477013 )
2018
42
Congenital cytomegalovirus infection. ( 29503048 )
2018
43
Pilot Study of Model-Based Dosage Individualization of Ganciclovir in Neonates and Young Infants with Congenital Cytomegalovirus Infection. ( 29507070 )
2018
44
Higher Expectations for a Vaccine To Prevent Congenital Cytomegalovirus Infection. ( 30018143 )
2018
45
Reply to Gantt et al., "Higher Expectations for a Vaccine To Prevent Congenital Cytomegalovirus Infection". ( 30018144 )
2018
46
Impact of congenital cytomegalovirus infection on transcriptomes from archived dried blood spots in relation to long-term clinical outcome. ( 30024899 )
2018
47
Usefulness of a flow chart for targeted screening of congenital cytomegalovirus-related hearing loss. ( 30040746 )
2018
48
New findings in congenital cytomegalovirus infection: The spectrum from asymptomatic to symptomatic infection. ( 30049399 )
2018
49
Intraventricular haemorrhage as the first manifestation of congenital Cytomegalovirus infection. ( 30084424 )
2018
50
A Twenty-Year Retrospective Diagnosis of Congenital Cytomegalovirus Infection. ( 30104109 )
2018

Variations for Congenital Cytomegalovirus

Expression for Congenital Cytomegalovirus

Search GEO for disease gene expression data for Congenital Cytomegalovirus.

Pathways for Congenital Cytomegalovirus

Pathways related to Congenital Cytomegalovirus according to GeneCards Suite gene sharing:

(show all 33)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.39 CCL2 IL1B TLR2 TNF
2 12.33 CCL2 IL1B TLR2 TNF
3
Show member pathways
12.17 CCL2 IL1B TNF
4
Show member pathways
12.09 IL1B TLR2 TNF
5
Show member pathways
12.07 CCL2 IL1B TLR2 TNF
6 12.06 IL1B TLR2 TNF
7
Show member pathways
12.05 IL1B TLR2 TNF
8
Show member pathways
12.02 IL1B TLR2 TNF
9 11.92 CCL2 IL1B TNF
10
Show member pathways
11.88 IL1B TLR2 TNF
11 11.87 IL1B PPARG TNF
12
Show member pathways
11.85 IL1B TLR2 TNF
13 11.82 CCL2 IL1B TNF
14 11.79 CCL2 IL1B TNF
15 11.77 CCL2 IL1B TNF
16 11.71 CCL2 IL1B TNF
17 11.68 IL1B TLR2 TNF
18 11.58 CCL2 IL1B TLR2 TNF
19 11.57 IL1B KLRK1 TNF
20 11.45 CCL2 IL1B TNF
21 11.37 IL1B TLR2 TNF
22 11.31 CCL2 IL1B PPARG TNF
23 11.27 CCL2 IL1B TNF
24 11.16 IL1B TNF
25 11.14 IL1B TNF
26 11.11 IL1B TNF
27 11.04 CCL2 IL1B TNF
28 10.96 IL1B TNF
29 10.95 PPARG TNF
30 10.94 CCL2 IL1B TLR2
31 10.94 CCL2 IL1B TLR2 TNF
32 10.71 CCL2 IL1B KLRK1 TLR2 TNF
33 10.64 CCL2 IL1B TNF

GO Terms for Congenital Cytomegalovirus

Cellular components related to Congenital Cytomegalovirus according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 gap junction GO:0005921 8.96 GJB2 GJB6
2 connexin complex GO:0005922 8.62 GJB2 GJB6

Biological processes related to Congenital Cytomegalovirus according to GeneCards Suite gene sharing:

(show all 36)
# Name GO ID Score Top Affiliating Genes
1 immune response GO:0006955 9.96 CCL2 IL1B TLR2 TNF
2 negative regulation of cell proliferation GO:0008285 9.94 GJB6 IL1B PPARG TLR2
3 inflammatory response GO:0006954 9.9 CCL2 IL1B TLR2 TNF
4 positive regulation of NF-kappaB transcription factor activity GO:0051092 9.83 IL1B TLR2 TNF
5 positive regulation of DNA-binding transcription factor activity GO:0051091 9.77 IL1B PPARG TNF
6 defense response to Gram-positive bacterium GO:0050830 9.76 KLRK1 TLR2 TNF
7 cellular response to organic cyclic compound GO:0071407 9.73 CCL2 IL1B TNF
8 positive regulation of interleukin-6 production GO:0032755 9.7 IL1B TLR2 TNF
9 positive regulation of NIK/NF-kappaB signaling GO:1901224 9.69 IL1B TLR2 TNF
10 negative regulation of vascular endothelial cell proliferation GO:1905563 9.67 CCL2 PPARG
11 negative regulation of neurogenesis GO:0050768 9.67 IL1B TNF
12 positive regulation of chemokine production GO:0032722 9.65 TLR2 TNF
13 microglial cell activation GO:0001774 9.65 TLR2 TNF
14 positive regulation of oligodendrocyte differentiation GO:0048714 9.64 PPARG TLR2
15 negative regulation of lipid catabolic process GO:0050995 9.63 IL1B TNF
16 positive regulation of glial cell proliferation GO:0060252 9.63 IL1B TNF
17 positive regulation of interferon-gamma production GO:0032729 9.63 IL1B KLRK1 TNF
18 regulation of I-kappaB kinase/NF-kappaB signaling GO:0043122 9.62 IL1B TNF
19 positive regulation of membrane protein ectodomain proteolysis GO:0051044 9.62 IL1B TNF
20 response to lipopolysaccharide GO:0032496 9.62 GJB2 GJB6 IL1B TLR2
21 positive regulation of heterotypic cell-cell adhesion GO:0034116 9.61 IL1B TNF
22 positive regulation of nitric-oxide synthase biosynthetic process GO:0051770 9.61 CCL2 TLR2
23 positive regulation of nitric oxide biosynthetic process GO:0045429 9.61 IL1B KLRK1 TNF
24 positive regulation of chemokine biosynthetic process GO:0045080 9.58 IL1B TNF
25 regulation of establishment of endothelial barrier GO:1903140 9.57 IL1B TNF
26 cellular response to lipopolysaccharide GO:0071222 9.56 CCL2 IL1B KLRK1 TNF
27 positive regulation of neuroinflammatory response GO:0150078 9.55 IL1B TNF
28 positive regulation of fever generation GO:0031622 9.54 IL1B TNF
29 sequestering of triglyceride GO:0030730 9.48 IL1B TNF
30 negative regulation of natural killer cell chemotaxis GO:2000502 9.4 CCL2 KLRK1
31 positive regulation of calcidiol 1-monooxygenase activity GO:0060559 9.37 IL1B TNF
32 response to immobilization stress GO:0035902 9.36 PPARG
33 protein kinase B signaling GO:0043491 9.33 CCL2 IL1B TNF
34 chronic inflammatory response to antigenic stimulus GO:0002439 9.19 TNF
35 positive regulation of interleukin-8 production GO:0032757 9.13 IL1B TLR2 TNF
36 lipopolysaccharide-mediated signaling pathway GO:0031663 8.92 CCL2 IL1B TLR2 TNF

Molecular functions related to Congenital Cytomegalovirus according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytokine activity GO:0005125 8.8 CCL2 IL1B TNF

Sources for Congenital Cytomegalovirus

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....